



Year: 2013

Epidemiology and Outcome of Human Fusariosis as reflected in published cases of the disease

Schmidig, Doris

Abstract: Background: *Fusarium* is a mold mainly known as plant and animal pathogen. Recently, there has been an increasing number of reports about fusarium infection in humans, especially as opportunistic infection in immunocompromised patients with a significant morbidity and mortality rate. The aim of this study is to further elucidate the behavior of fusariosis in humans. Methods: We analyzed all reports of *Fusarium* infection in the English and German literature from 1958 to 2007. Data about the age, gender, underlying condition, symptoms, *Fusarium* species, treatment and outcome were analyzed. Results: 213 cases with either histologically or culture proven infection were included. 62.5% (n=133) were male. The median age of the patients was 39.9 years (range: 0.04-82 years). The overall mortality rate was 34.7% (n=74), with a direct correlation between the underlying condition, the immune status of the patient and the site of infection. No underlying condition was found in only 4.2% (n=9) of all cases. All of them survived and none of them had a disseminated disease. A disseminated infection was detected in 40% (n=86) of all analyzed cases with fusariosis. The second leading site of *Fusarium* infection was the skin 22.5% (n=48) and eye 15% (n=33). *Fusarium solani* was the most frequent species. 92.5% (n=197) of all patients received antifungal therapy. The most frequent used antifungal agent was amphotericin B deoxycholate and its liposomal equivalent. Only 6 patients received no treatment at all, neither surgery nor any sort of medication. 4 of them died. Conclusion: From the first case in 1958 an increasing number of cases were published each decade with a peak between 1990-1999. The outcome depends on the site of infection and the immune status of the patient. Disseminated Fusariosis in immunocompromised patients had a very poor outcome. Usually a recovery is achieved as soon as the immune status of the patient improves.

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-73145>

Dissertation

Originally published at:

Schmidig, Doris. Epidemiology and Outcome of Human Fusariosis as reflected in published cases of the disease. 2013, University of Zurich, Faculty of Medicine.

Universitätsspital Zürich
Klinik und Poliklinik für Innere Medizin
Prof. Dr. med. Edouard Battegay

Arbeit unter Leitung von Prof. Dr. med. Edouard Battegay
und PD Dr. med. Alexander Imhof

Epidemiology and outcome of Human Fusariosis

INAUGURAL-DISSERTATION
zur Erlangung der Doktorwürde
der Medizinischen Fakultät
der Universität Zürich

vorgelegt von
Doris Schmidig
aus Schaffhausen

Genehmigt auf Antrag von Prof. Dr. med. Edouard Battegay
Zürich 2012

Table of contents

1. Summary	3
2. Introduction	5
3. Methods	7
4. Results.....	8
Demographic characteristics	8
Change of Fusarium infections during study period	9
Sites of infection	10
Clinical manifestation	11
Microbiological findings	11
Treatment.....	14
Outcome.....	18
5. Discussion	20
6. References	24
7. Curriculum vitae	39

1. Summary

Background: Fusarium is a mold mainly known as plant and animal pathogen. Recently, there has been an increasing number of reports about fusarium infection in humans, especially as opportunistic infection in immunocompromised patients with a significant morbidity and mortality rate. The aim of this study is to further elucidate the behavior of fusariosis in humans.

Methods: We analyzed all reports of Fusarium infection in the English and German literature from 1958 to 2007. Data about the age, gender, underlying condition, symptoms, Fusarium species, treatment and outcome were analyzed.

Results: 213 cases with either histologically or culture proven infection were included. 62.5% (n=133) were male. The median age of the patients was 39.9 years (range: 0.04-82 years). The overall mortality rate was 34.7% (n=74), with a direct correlation between the underlying condition, the immune status of the patient and the site of infection. No underlying condition was found in only 4.2% (n=9) of all cases. All of them survived and none of them had a disseminated disease. A disseminated infection was detected in 40% (n=86) of all analyzed cases with fusariosis. The second leading site of Fusarium infection was the skin 22.5% (n=48) and eye 15% (n=33). *Fusarium solani* was the most frequent species. 92.5% (n=197) of all patients received antifungal therapy. The most frequent used antifungal agent

was amphotericin B deoxycholate and its liposomal equivalent. Only 6 patients received no treatment at all, neither surgery nor any sort of medication. 4 of them died.

Conclusion: From the first case in 1958 an increasing number of cases were published each decade with a peak between 1990-1999. The outcome depends on the site of infection and the immune status of the patient. Disseminated Fusariosis in immunocompromised patients had a very poor outcome. Usually a recovery is achieved as soon as the immune status of the patient improves.

2. Introduction

The mold *Fusarium* is a common soil saprophyte, and it is worldwide distributed in plants, soil and water (49, 53, 57, 92). *Fusarium* species were also detected in the hospital water systems and outdoor air (94). *Fusarium* species are important plant pathogens. *Fusarium* infections in humans are rare and used to be mostly associated with superficial mycosis (53). However, locally invasive and systemic infections are observed with increasing frequency in immunocompromised patients and have recently emerged as opportunistic fungal infections among these patients (53, 94). With the widespread use of cytoreductive and immunosuppressive therapy in patients with hematological malignancies, Fusariosis has recently become an emerging disease in immunocompromised patients (8, 9, 24, 50, 87, 94).

Fusarium species is a fungus of hyalohyphomycosis along with other fungi such as *Penicillium* species, or *Aspergillus* species.

More than 50 species of *Fusarium* have been described but only a few of them have been recognized as pathogenic for humans (94).

The most common is *Fusarium solani* (9, 94). Followed by *Fusarium oxysporum* (2, 3, 7, 15, 23, 37, 40, 44, 54, 58, 62, 68, 83, 85, 93, 102-104, 109, 110, 113, 114, 116, 117, 121, 128, 131, 138, 140) and

Fusarium moniliforme (28, 32, 43, 48, 63, 89, 98, 109, 136, 138, 142).

Others found in the literature are *Fusarium verticillioides* (38, 78, 105, 119, 137), *Fusarium proliferatum* (16, 59, 108, 129), *Fusarium dimerum* (12, 20, 26, 68, 71), *Fusarium chlamydosporum* (66, 125), *Fusarium roseum* (99), *Fusarium conglutinans* (76), *Fusarium*

napiforme (81), *Fusarium sacchari* (50) and *Fusarium polyphialidicum* (51). The fungus *Fusarium* sp. possesses several virulence factors including the production mycotoxins. These mycotoxins can suppress humoral and cellular immunity, and cause tissue breakdown.

Fusarium spp. also have the ability to adhere to prosthetic material (contact lenses, catheters) (92).

The clinical manifestation of fusariosis correlates directly with the immune status of the patient and the portal of entry (94). An infection in healthy patients is rare and occurs usually only after direct inoculation or breakdown of the tissue barrier (79). It affects mostly skin and eyes (19, 53, 57). However, Fusariosis is one of the most common cause of fungal keratitis world-wide (19).

In immunocompromised patients, especially those with prolonged neutropenia the *Fusarium* infection often results as an invasive or disseminated disease (49). The most frequent clinical manifestation of disseminated fusariosis in these patients is refractory fever despite antibacterial and antifungal therapy with typical cutaneous lesions and positive blood culture (49, 79, 87, 94).

Due to this fact and the knowledge of the increasing number of immunosuppressed patient the aim of this study is to further elucidate the pattern of the *Fusarium* infection. We reviewed the English and German language literature for all cases of fusariosis, from the original case report in 1958 to 2007. In this review, we sought to understand the pattern of the infection, whether the infection is associated with specific host factors, the portal of entry, treatment and outcome.

3. Methods

We conducted a systematic literature search of the MEDLINE, to identify all reported cases with an infection due to *Fusarium* sp. After the initial search we scanned the references listed on each publication to gain additional cases. Only cases with either histologically or culture proven *Fusarium* infection were included. Data about the anatomical location of the infection, risk factors (e.g. immunosuppression, antibiotic treatment, steroids, and injury), age and gender of the patient, treatment and outcome were collected and analyzed.

A disseminated infection was defined as an infection at two or more noncontiguous sites.

4. Results

213 cases of fusariosis were included in our analysis. In 1958, the first case of *Fusarium* infection was mentioned in a patient after an eye injury due to a cowtail (83). The inflamed eye was treated with antibiotics and steroids without improvement. Pus in the anterior chamber and a perforated ulcer developed. A smear finally proved a *Fusarium* infection. The eye had to be enucleated in order to achieve a complete recovery from the infection. From this first case of *Fusarium* infection an increasing number of cases were published in the literature in each decade, reaching a peak between 1990-1999 (figure 1).

Demographic characteristics

The median age of all patients was 38.95 years with a range from 0.04-82 years. 72 patients (33.8%) were over the age of 50 years, 26 patients (12.2%) under the age of 10 years. A total of 62.4% (n=133) of all *Fusarium* infections occurred in males, 35.2% (n= 75) in females. In 2% (n=5) of all cases the gender of the patient was not mentioned at all.

The overall mortality rate was 34.7% (74 of 213 Patients did not survive the infection), 49.7% (n=106) achieved a complete recovery. In the remaining 15.6% (n=33) there was either a stable disease or the patient was lost to follow-up.

The most common underlying condition and major risk factor to become infected from a *Fusarium* sp. was any antibiotic treatment (63.9%), followed by hematologic malignancies (44.1%). Predisposing job or hobbies, such as farming or gardening were found in 6.1% of the cases. However, 77.4% (n=164) of all patients had more than just one risk factor. No underlying condition was found in only 9 cases (4.2%). All 9 cases had a localized infection and survived (table 1).

Change of *Fusarium* infections during study period

In 1950-1959 trauma was the most common underlying condition. After 1960 the leading underlying condition in each decade was any use of antibiotics. Hematologic malignancies were not known as underlying condition until 1970. After 1980 it became the second most underlying condition with a peak in 1990-1999 (figure 1). However, over all decades the hematologic malignancies with consecutive chemotherapy and neutropenia, which requires the broad use of antibiotics, are the most important risk factors of *Fusarium* infections.

Besides the medical progress with its associated ICU treatments, foreign devices in the body, such as catheters and grafts are frequently associated with *Fusarium* infections.

Sites of infection

Fusarium infection can be superficial, locally invasive or disseminated. The site of infection depends mainly on the underlying condition and correlates directly with the immune status of the patient and the site of entry (table 1).

A disseminated infection was diagnosed in 74.4% (n=64) of all cases associated with a hematologic malignancy. Chemotherapy and neutropenia are also important risk factors to develop a disseminated infection (65.1% of all cases, n=56 in both cases).

In 69.6% (n=23) of all eye infections there was a prior antibiotic treatment. The second underlying risk factor for eye infections was the use of local steroids (51.5%, n=17), followed by foreign devices in the eye such as contact lenses (42.4%, n=14) and trauma (36.3%, n=12).

Regarding the skin infection, the most common risk factor was also the use of antibiotics (47.9%, n=23), followed by hematologic malignancies (39.6%, n=19), chemotherapy (35.4%, n=17) and neutropenia (29.1%, n=14).

Positive blood cultures was obviously often associated with foreign devices, such as catheters and grafts (81.9%, n=9).

In most cases of nail infections no underlying condition could be found (71.5%).

Bone infections were often associated with diabetes mellitus (50%),

All patients with Fusarium endocarditis had an intravascular catheter.

The two cases with peritonitis were both associated with peritoneal dialysis.

Clinical manifestation

The clinical manifestation depended on the site of infection.

The most frequent clinical manifestation in patients with disseminated fusariosis was refractory fever. Further typical cutaneous lesions were mentioned in 44% of all disseminated cases. Skin lesions presented themselves as erythematous painful cutaneous or subcutaneous papular nodules.

Pulmonary infiltrations were found in 23% of the cases with disseminated fusariosis. An eye infection usually presents itself by decreasing vision and painful watery injected eyes, later with corneal ulcer. In nail infection a yellow or white discoloration periungular was seen.

Microbiological findings

The most common species was *F. solani* in 34.3%, followed by *F. oxysporum* in 17.8%, *F. moniliforme* 5.6%. Only sporadic infections with *F. verticilloides*, *F. proliferatum*, *F. dimerum*, *F. roseum*, *F. chlamydosporum*, *F. conglutinans*, *F. polyphialdicum*, *F. napiforme*, *F. sachari* were reported (table 1). In 26.4% (n=63) the exact species was not documented. *F. solani* seems to be the most virulent species. 34.9% (n=25) of all disseminated infections are caused by *F. solani* and 30.1% (n=22) of all patients with *F. solani* infection died. *F. oxysporum* was in 17.4% (n=15) associated with a disseminated disease, *F. moniliforme* and *F. verticilliodes* in 5.8% (n=5). *F. proliferatum* and *F. dimerum* were only found in 3 patients with disseminated disease.

Figure 1: Number of patients mentioned in the literature with Fusarium infection per decade.




Table 1: Demographic and clinical characteristics

Characteristic	No. of patients	No. of patients who died
Total	213	74/213 (34.7%)
Age		
• mean	38.95	
• range	0.04-82	
Sex		
• male	133 (62.4%)	
• female	75 (35.2%)	
• unknown	5 (2.4%)	
Underlying condition		
• Medication		
- steroids	31 (14.6%)	9 (29%)
- antibiotics	136 (63.9%)	56 (41.2%)
• Tumor		
- solid organ	15 (7%)	7 (46.7%)
- hematologic	94 (44.1%)	46 (48.9%)
• Transplantation		
- kidney	3 (1.4%)	2 (66.7%)
- liver	1 (0.5%)	0
- heart/liver	1 (0.5%)	0
- lung	3 (1.4%)	2 (66.7%)
- bone marrow	27 (12.7%)	20 (74.0%)
• Trauma/burns	34 (16%)	3 (8.8%)
• Foreign body		
- catheter	25 (11.7%)	11 (44%)
- contact lens	15 (7%)	0
- graft	3 (1.4%)	3 (100%)
- nasogastric tube	2 (0.9%)	0
- dialysis	3 (1.4%)	0
• no	9 (4.2%)	0
Site of infection		
• disseminated	86 (40.4%)	50 (58.1%)
• skin	48 (22.5%)	12 (25%)
• eye	33 (15.5%)	0 (0%)
• ORL	10 (4.7%)	4 (40%)
• blood	11 (5.2%)	1 (9.1%)
• nail	8 (3.8%)	0
• bone	6 (2.8%)	0
• joint	3 (1.4%)	1 (33.3%)
• lung	3 (1.4%)	1 (33.3%)
• endocarditis	3 (1.4%)	3 (100%)
• peritoneum	2 (0.9%)	0 (0%)
Species		
• <i>F. solani</i>	73 (34.3%)	22 (30.1%)
• <i>Species unknown</i>	63 (29.6%)	22 (34.9%)
• <i>F. oxysporum</i>	38 (17.8%)	14 (36.8%)
• <i>F. moniliforme</i>	12 (5.6%)	6 (50%)
• <i>F. verticillioides</i>	7 (3.3%)	3 (42.9%)
• <i>F. proliferatum</i>	7 (3.3%)	2 (28.6%)
• <i>F. dimerum</i>	5 (2.4%)	3 (60%)
• <i>F. roseum</i>	2 (0.9%)	0 (0%)
• <i>F. chlamydosporum</i>	2 (0.9%)	1 (50%)
• <i>F. conglutinans</i>	1 (0.5%)	0
• <i>F. polyphialidicum</i>	1 (0.5%)	0
• <i>F. napiforme</i>	1 (0.5%)	0

Treatment

The treatment depended on the site of infection. 197 (92.5%) of the reviewed 213 cases were treated with any antifungal therapy. Most of the patients received a combination of different antifungal pharmaceuticals. Only 6 patients (3 with disseminated, 1 with burns and 2 with skin infection) received no treatment at all, 4 of them died, among them the 2 cases with disseminated infections and the one with burns. In 3 of these cases the diagnosis of *Fusarium* infection was made post mortem.

Surgery alone was used in 7 patients with superficial infection. All of them survived.

The most widely used antifungal therapy was amphotericin B deoxycholate (62.5%, n=133) with its first use in 1964. The second most used was liposomal amphotericin B (17.5%, n=37), first administered in 1991. Followed by flucytosin (n=30), fluconazole (11.3%, n=24), voriconazole (12.2%, n=26), itraconazole (9.4%, n=20), ketokonazole (8.5%, n=18) and rifampicin (7.0%, n=15).

Besides the antifungal therapy and surgery the use of Granulocyte transfusions and G-CSF transfusion was used.

Between 1958-1959 none of the above mentioned antifungal therapy was known. Surgery was the treatment of choice. Later on, between 1960-1969 the first antifungal therapy came in place. For a long time amphotericin B deoxycholate was the only known antifungal pharmaceutical, until 1979 when flucytosin came in place, followed by ketokonazole (1986). The first use of G-CSF was mentioned in 1990.

In 1991 the first use of liposomal amphotericin B was reported, 1992 the first use of fluconazole, 1994 itraconazole and 2003 voriconazole. Many patients (27.2%, n=58) received a combination of antifungal agents. Rifampicin was never used as a single drug, but always in combination with an antifungal agent, most often with amphotericin B. In 56 of the 58 cases with a combination antifungal therapy, amphotericin B was one component of the combination. In the later decades voriconazole was widely used in a combination therapy. The most frequently used combination was amphotericin B/flucytosin (9.4%, n=20), followed by amphotericin B/voriconazole (3.8%, n=8), amphotericin B/rifampicin (3.3%, n=7) and amphotericin B/ketoconazole (1.9%, n=4). Other combinations used where amphotericin B/fluconazole in 3 cases, amphotericin B/itraconazole in 2 cases and ketoconazole/rifampicin in 1 case.

Triple combinations were used in 12 cases:

- amphotericin B/flucytosin/rifampicin (n=2)
- rifampicin/ketoconazole/amphotericin B (n=2)
- amphotericin B/flucytosin/ketoconazole (n=2)
- amphotericin B/voriconazole/fluconazole (n=2)
- amphotericin B/fluconazole/itraconazole (n=1)
- amphotericin B/voriconazole/itraconazole (n=1)
- amphotericin B/flucytosin/itraconazole (n=1)
- amphotericin B/fluconazole/rifampicin (n=1)

The use of voriconazole in combination with another antifungal drug seems to be a successful treatment with a recovery rate of 90%. On the other hand rifampicin in combination with an antifungal agent seems to be a poor choice: 69.2% of the patients didn't survive the infection. 53.5% of the patient who received a combination therapy survived.

Table 2: Treatment administered to 213 patients with fusariosis

Treatment	No. of patients	No. of patients who died
Amphotericin B		
- deoxycholate	133 (17.5%)	56 (42.1%)
- lipid/liposomal	37 (17.5%)	12 (32.4%)
Flucytosin	30 (14.1%)	17 (20.3%)
Fluconazole	24 (11.3%)	11 (45.8%)
Voriconazole	26 (12.2%)	1 (3.8%)
Itraconazole	20 (9.4%)	6 (30%)
Ketoconazole	18 (8.5%)	5 (27.8%)
Rifampicin	13 (6.1%)	9 (69.2%)
Surgery	75 (35.2%)	13 (17.3%)
G-Transfusion	12 (5.7%)	6 (50%)
G-CSF	25 (11.8%)	12 (42.9%)
No therapy	6 (2.9%)	4 (33.3%)

Outcome

The overall mortality was 34.7% (n=74). A complete recovery was achieved in 49.7%. 15.5% of the patients were lost to follow-up was. The mortality rate was strongly associated with the underlying condition and the site of infection. A disseminated infection is obviously associated with a worse outcome. 58.1% of all patients with disseminated infections died, whereas only in 36.0% a complete recovery was achieved. A disseminated fusariosis was only seen in immunocompromised patients.


All 3 patients with a *Fusarium* endocarditis didn't survive. 25% of the patient with a skin *Fusarium* infection died. An eye infection led never to death.

An underlying hematologic malignancy was the most important risk factor for death. 48.9% (n=46) of all patients with hematologic malignancies didn't survive the infection.

All patients with no underlying condition survived the infection.

Regarding the mortality rate per decade there is a notable increase in the mortality rate each decade, reaching a peak in the 1990-1999 with 51.9% patients with fusariosis dying (figure 2). This trend was attributed to the widespread and, immunosuppressive therapy and increasing use of antibiotics. Finally a decrease of the death rate was recognizable in the time of 2000-2007 with a mortality rate of 16.4% (12 of 69 patients). In most cases it was seen that as soon as the patients achieves a recovery of its own body defense, he will recover from the infection.

Figure 2: number of patients (light) and death rate in % (dark) compared to decade



5. Discussion

Fusariosis is an emerging disease, especially in immunocompromised patients. *Fusarium spp.* causes a broad spectrum of infections in humans, including superficial, locally invasive, and disseminated infections (94). To our knowledge, this is the first study including all published *Fusarium* infections. The first reported case of a *Fusarium* infection was in 1958 (83). Unlike other known filamentous fungal pathogens, *Fusarium* affects mostly immunocompromised hosts. Our study showed that, in contrast to other mold infections, such as zygomycetes (112), diabetes or solid tumors don't seem to be important risk factors to get infected with *Fusarium spp.* Only a few cases, namely 10 were found in patients with solid tumor. Only 4 cases were observed in patients with diabetes mellitus as a risk factor. All of them had a localized infection, either a skin infection or an infection in the otorhinolaryngological site. Each one achieved full recovery. No underlying condition was found in 9 cases at all.

The most important risk factor for severe fusariosis is prolonged neutropenia in patients suffering from a hematologic malignancy, including especially hematopoietic stem cell transplantations.

Fusarium infection is in the vast majority of the cases caused by a breakdown of the human defense. Either by trauma which affects the natural skin defense, or in immunocompromised hosts. Fusariosis is rare in a healthy person and occurs usually only after direct inoculation or tissue breakdown (as caused by trauma, severe burns

or foreign body). No disseminated infection was found in healthy people. However, infections include keratitis, onychomycosis and occasionally peritonitis and cellulitis. Treatment is usually successful and requires surgery, removal of a possible foreign body as well as antifungal therapy.

In disseminated fusariosis refractory fever and cutaneous lesions are the most important symptoms. Type of skin lesions includes ecthyma-like, target, and multiple subcutaneous nodules. Skin lesions lead to diagnosis in > 50% of patients and precede fungemia by approximately 5 days. In contrast to aspergillosis, fusariosis frequently shows positive blood cultures. This is because *Fusarium spp.* sporulate, which facilitates bloodborne disseminated growth (13).

The culture methods typically have a low sensitivity for identifying the *Fusarium* species. Species identification may be difficult and may require the use of molecular techniques. PCR methods are available but the identification is complex and requires a highly skilled laboratory staff (27). The use of mass spectrometry to identify the *Fusarium ssp.* has recently gained popularity (27). Matrix-assisted laser desorption ionization-time of light (MALDI-TOF) is a tool that has been used to characterize fungi (27, 31, 132). But so far there is no standard protocol or validated database to use the MALDI-TOF in a routine lab (27). The most common species found in our study was *F. solani*, followed by *F. oxysporum*, *F. moniliforme*, *F. verticilloides*, *F. proliferatum* and *F. dimerum*. In our study, *F. solani* seemed to be the most virulent species with the highest mortality rate.

Optimal treatment has not been established, yet. Anecdotal successes have been reported with various agents (high-dose amphotericin B, lipid-based amphotericin B formulations, itraconazole, voriconazole) and with cytokine-stimulated granulocyte transfusions. A study of Astor et al. (13) analyzed the susceptibility of the different *Fusarium spp.* to antifungals in vitro. The result showed that terbinafine was most effective, followed by voriconazole and amphotericin B. In our study terbinafine was not used in the treatment of fusariosis. However, Combinationtherapies containing voriconazole showed a favorable outcome. Further studies should be conducted addressing the terbinafine in combination with voriconazole in treatment of an infection due to *Fusarium spp.*

Given the poor prognosis associated with disseminated fusariosis in immunocompromised patients, prevention is the cornerstone of management (94). The high risk patients have to be in rooms with HEPA filters. Further, contact with reservoirs of *Fusarium spp.* such as food or tap water should be avoided.

In conclusion, infections by *Fusarium spp.* can be superficial or limited to single organs in non immunocompromised host. Such infections are rare and tend to respond well to therapy. By contrast, disseminated fusariosis occurs in the immunocompromised host, especially in hemato-oncological patients with severe and prolonged neutropenia. These patients die frequently in this setting, and successful outcome is determined largely by the degree and persistence of immunosuppression. Fusariosis may be clinically

suspected on the basis of the clinical presentation and laboratory findings. A prompt therapy should be started.

6. References

1. Abramowsky CR, Quinn D, Bradford WD, Conant NF. Systemic infection by fusarium in a burned child. The emergence of a saprophytic strain. *J Pediatr* 84 (4): 561-4, 1974.
2. Agamanolis DP, Kalwinsky DK, Krill CE, Jr., Dasu S, Halasa B, Galloway PG. Fusarium meningoenophalitis in a child with acute leukemia. *Neuropediatrics* 22 (2): 110-2, 1991.
3. Albisetti M, Lauener RP, Gungor T, Schar G, Niggli FK, Nadal D. Disseminated Fusarium oxysporum infection in hemophagocytic lymphohistiocytosis. *Infection* 32 (6): 364-6, 2004.
4. Alfonso EC, Cantu-Dibildox J, Munir WM, Miller D, O'Brien TP, Karp CL, Yoo SH, Forster RK, Culbertson WW, Donaldson K, Rodila J, Lee Y. Insurgence of Fusarium keratitis associated with contact lens wear. *Arch Ophthalmol* 124 (7): 941-7, 2006.
5. Alvarez-Franco M, Reyes-Mugica M, Paller AS. Cutaneous Fusarium infection in an adolescent with acute leukemia. *Pediatr Dermatol* 9 (1): 62-5, 1992.
6. Ammari LK, Puck JM, McGowan KL. Catheter-related Fusarium solani fungemia and pulmonary infection in a patient with leukemia in remission. *Clin Infect Dis* 16 (1): 148-50, 1993.
7. Anaissie E, Kantarjian H, Jones P. Fungal infection caused by Fusarium in cancer patients. *Am J Clin Oncol* 10 (1): 86-8, 1987.
8. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. *Eur J Clin Microbiol Infect Dis* 8 (4): 323-30, 1989.
9. Anandi V, Vishwanathan P, Sasikala S, Rangarajan M, Subramaniyan CS, Chidambaram N. Fusarium solani breast abscess. *Indian J Med Microbiol* 23 (3): 198-9, 2005.
10. Arney KL, Tiernan R, Judson MA. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient. *Chest* 112 (4): 1128-30, 1997.

11. Arrese JE, Pierard-Franchimont C, Pierard GE. Fatal hyalohyphomycosis following *Fusarium* onychomycosis in an immunocompromised patient. *Am J Dermatopathol* 18 (2): 196-8, 1996.
12. Austen B, McCarthy H, Wilkins B, Smith A, Duncombe A. Fatal disseminated fusarium infection in acute lymphoblastic leukaemia in complete remission. *J Clin Pathol* 54 (6): 488-90, 2001.
13. Azor M, Gene J, Cano J, Sutton DA, Fothergill AW, Rinaldi MG, Guarro J. In vitro antifungal susceptibility and molecular characterization of clinical isolates of *Fusarium verticillioides* (*F. moniliforme*) and *Fusarium thapsinum*. *Antimicrob Agents Chemother* 52 (6): 2228-31, 2008.
14. Bader M, Jafri AK, Krueger T, Kumar V. *Fusarium* osteomyelitis of the foot in a patient with diabetes mellitus. *Scand J Infect Dis* 35 (11-12): 895-6, 2003.
15. Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of *Fusarium* nail infection: report of three cases. *Br J Dermatol* 136 (3): 424-7, 1997.
16. Barrios NJ, Kirkpatrick DV, Murciano A, Stine K, Van Dyke RB, Humbert JR. Successful treatment of disseminated *Fusarium* infection in an immunocompromised child. *Am J Pediatr Hematol Oncol* 12 (3): 319-24, 1990.
17. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. *Br J Dermatol* 126 Suppl 39: 40-6, 1992.
18. Benjamin RP, Callaway L, Conant NF. Facial granuloma associated with fusarium infection. *Arch Dermatol* 101 (5): 598-600, 1970.
19. Bernal MD, Acharya NR, Lietman TM, Strauss EC, McLeod SD, Hwang DG. Outbreak of *Fusarium* keratitis in soft contact lens wearers in San Francisco. *Arch Ophthalmol* 124 (7): 1051-3, 2006.
20. Bigley VH, Duarte RF, Gosling RD, Kibbler CC, Seaton S, Potter M. *Fusarium dimerum* infection in a stem cell transplant recipient treated successfully with voriconazole. *Bone Marrow Transplant* 34 (9): 815-7, 2004.

21. Blazar BR, Hurd DD, Snover DC, Alexander JW, McGlave PB. Invasive *Fusarium* infections in bone marrow transplant recipients. *Am J Med* 77 (4): 645-51, 1984.
22. Bleggi-Torres LF, de Medeiros BC, Neto JZ, Loddo G, Telles FQ, de Medeiros CR, Pasquini R. Disseminated *Fusarium* sp. infection affecting the brain of a child after bone marrow transplantation. *Bone Marrow Transplant* 18 (5): 1013-5, 1996.
23. Bourguignon RL, Walsh AF, Flynn JC, Baro C, Spinos E. *Fusarium* species osteomyelitis. Case report. *J Bone Joint Surg Am* 58 (5): 722-3, 1976.
24. Boutati EI, Anaissie EJ. *Fusarium*, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. *Blood* 90 (3): 999-1008, 1997.
25. Brint JM, Flynn PM, Pearson TA, Pui CH. Disseminated fusariosis involving bone in an adolescent with leukemia. *Pediatr Infect Dis J* 11 (11): 965-8, 1992.
26. Camin AM, Michelet C, Langanay T, de Place C, Chevrier S, Gueho E, Guiguen C. Endocarditis due to *Fusarium dimerum* four years after coronary artery bypass grafting. *Clin Infect Dis* 28 (1): 150, 1999.
27. Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. *Fusarium* infection in lung transplant patients: report of 6 cases and review of the literature. *Medicine (Baltimore)* 90 (1): 69-80, 2011.
28. Castagnola E, Garaventa A, Conte M, Barretta A, Faggi E, Viscoli C. Survival after fungemia due to *Fusarium moniliforme* in a child with neuroblastoma. *Eur J Clin Microbiol Infect Dis* 12 (4): 308-9, 1993.
29. Caux F, Aractingi S, Baurmann H, Reygagne P, Dombret H, Romand S, Dubertret L. *Fusarium solani* cutaneous infection in a neutropenic patient. *Dermatology* 186 (3): 232-5, 1993.
30. Chaulk CP, Smith RW, Feagler JR, Verdirame J, Commers JR. Fungemia due to *Fusarium solani* in an immunocompromised child. *Pediatr Infect Dis* 5 (3): 363-6, 1986.

31. Chen HY, Chen YC. Characterization of intact *Penicillium* spores by matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun Mass Spectrom* 19 (23): 3564-8, 2005.
32. Chi CC, Wang SH. Disseminated cutaneous *Fusarium moniliforme* infections in a leukemic child. *Int J Dermatol* 46 (5): 487-9, 2007.
33. Cho CT, Vats TS, Lowman JT, Brandsberg JW, Tosh FE. *Fusarium solani* infection during treatment for acute leukemia. *J Pediatr* 83 (6): 1028-31, 1973.
34. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. *Clin Infect Dis* 37 (2): 311-3, 2003.
35. Cudillo L, Girmenia C, Santilli S, Picardi A, Dentamaro T, Tendas A, de Fabritiis P. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. *Clin Infect Dis* 40 (8): 1212-3, 2005.
36. Cudillo L, Tendas A, Picardi A, Dentamaro T, Del Principe MI, Amadori S, de Fabritiis P. Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. *Ann Hematol* 85 (2): 136-8, 2006.
37. DiSalvo AF, Fickling AM. A case of nondermatophytic toe onychomycosis caused by *Fusarium oxysporum*. *Arch Dermatol* 116 (6): 699-700, 1980.
38. Dornbusch HJ, Buzina W, Summerbell RC, Lass-Flörl C, Lackner H, Schwinger W, Sovinz P, Urban C. *Fusarium verticillioides* abscess of the nasal septum in an immunosuppressed child: case report and identification of the morphologically atypical fungal strain. *J Clin Microbiol* 43 (4): 1998-2001, 2005.
39. Durand ML, Kim IK, D'Amico DJ, Loewenstein JI, Tobin EH, Kieval SJ, Martin SS, Azar DT, Miller FS, 3rd, Lujan BJ, Miller JW. Successful treatment of *Fusarium* endophthalmitis with voriconazole and *Aspergillus* endophthalmitis with voriconazole plus caspofungin. *Am J Ophthalmol* 140 (3): 552-4, 2005.

40. Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, Espinel-Ingroff A, Catteau B, Cordevant C, Camus D, Dei-Cas E, Bauters F, Delhaes L, De Botton S. Successful outcome of disseminated *Fusarium* infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. *J Clin Microbiol* 41 (10): 4898-900, 2003.
41. Ellis ME, Clink H, Younge D, Hainau B. Successful combined surgical and medical treatment of fusarium infection after bone marrow transplantation. *Scand J Infect Dis* 26 (2): 225-8, 1994.
42. Engelhard D, Eldor A, Polacheck I, Hardan I, Ben-Yehuda D, Amselem S, Salkin IF, Lopez-Berestein G, Sacks T, Rachmilewitz EA, et al. Disseminated visceral fusariosis treated with amphotericin B-phospholipid complex. *Leuk Lymphoma* 9 (4-5): 385-92, 1993.
43. Freidank H. Hyalohyphomycoses due to *Fusarium* spp.--two case reports and review of the literature. *Mycoses* 38 (1-2): 69-74, 1995.
44. Giaconi JA, Marangon FB, Miller D, Alfonso EC. Voriconazole and fungal keratitis: a report of two treatment failures. *J Ocul Pharmacol Ther* 22 (6): 437-9, 2006.
45. Girardi M, Glusac EJ, Imaeda S. Subcutaneous *Fusarium* foot abscess in a renal transplant patient. *Cutis* 63 (5): 267-70, 1999.
46. Girmenia C, Arcese W, Micozzi A, Martino P, Bianco P, Morace G. Onychomycosis as a possible origin of disseminated *Fusarium solani* infection in a patient with severe aplastic anemia. *Clin Infect Dis* 14 (5): 1167, 1992.
47. Goldblum D, Frueh BE, Zimmerli S, Bohnke M. Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex. *Cornea* 19 (6): 853-6, 2000.
48. Gradon JD, Lerman A, Lutwick LI. Septic arthritis due to *Fusarium moniliforme*. *Rev Infect Dis* 12 (4): 716-7, 1990.
49. Guarro J, Gene J. Opportunistic fusarial infections in humans. *Eur J Clin Microbiol Infect Dis* 14 (9): 741-54, 1995.

50. Guarro J, Nucci M, Akiti T, Gene J, Barreiro MD, Goncalves RT. Fungemia due to *Fusarium sacchari* in an immunosuppressed patient. *J Clin Microbiol* 38 (1): 419-21, 2000.
51. Guarro J, Rubio C, Gene J, Cano J, Gil J, Benito R, Morandier MJ, Miguez E. Case of keratitis caused by an uncommon *Fusarium* species. *J Clin Microbiol* 41 (12): 5823-6, 2003.
52. Guinvarc'h A, Guilbert L, Marmorat-Khuong A, Lavarde V, Chevalier P, Amrein C, Guillemain R, Berrebi A. Disseminated *Fusarium solani* infection with endocarditis in a lung transplant recipient. *Mycoses* 41 (1-2): 59-61, 1998.
53. Gupta AK, Baran R, Summerbell RC. *Fusarium* infections of the skin. *Curr Opin Infect Dis* 13 (2): 121-128, 2000.
54. Gutmann L, Chou SM, Pore RS. Fusariosis, myasthenic syndrome, and aplastic anemia. *Neurology* 25 (10): 922-6, 1975.
55. Guzman-Cottrill JA, Zheng X, Chadwick EG. *Fusarium solani* endocarditis successfully treated with liposomal amphotericin B and voriconazole. *Pediatr Infect Dis J* 23 (11): 1059-61, 2004.
56. Harris JJ, Downham TF, Jr. Unusual fungal infections associated with immunologic hyporeactivity. *Int J Dermatol* 17 (4): 323-30, 1978.
57. Hattori N, Shirai A, Sugiura Y, Li W, Yokoyama K, Misawa Y, Okuzumi K, Tamaki K. Onychomycosis caused by *Fusarium proliferatum*. *Br J Dermatol* 153 (3): 647-9, 2005.
58. Hemo I, Pe'er J, Polacheck I. *Fusarium oxysporum* keratitis. *Ophthalmologica* 198 (1): 3-7, 1989.
59. Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V. Successful treatment of *Fusarium proliferatum* pneumonia with posaconazole in a lung transplant recipient. *J Heart Lung Transplant* 23 (12): 1451-4, 2004.
60. Hsu CM, Lee PI, Chen JM, Huang LM, Wu MH, Chiu IS, Lee CY. Fatal *Fusarium* endocarditis complicated by hemolytic anemia and thrombocytopenia in an infant. *Pediatr Infect Dis J* 13 (12): 1146-8, 1994.

61. Jakle C, Leek JC, Olson DA, Robbins DL. Septic arthritis due to *Fusarium solani*. *J Rheumatol* 10 (1): 151-3, 1983.
62. Jorens PG, Van Den Heuvel PA, Van Cauwelaert PA, Parizel GA, Mertens AN. *Fusarium* endocarditis involving aortic valve following coronary artery surgery. *Eur Heart J* 11 (5): 476-8, 1990.
63. June CH, Beatty PG, Shulman HM, Rinaldi MG. Disseminated *Fusarium moniliforme* infection after allogeneic marrow transplantation. *South Med J* 79 (4): 513-5, 1986.
64. Kerr CM, Perfect JR, Craven PC, Jorgensen JH, Drutz DJ, Shelburne JD, Gallis HA, Gutman RA. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. *Ann Intern Med* 99 (3): 334-6, 1983.
65. Khoury H, Ball NJ. Disseminated fusariosis in a patient with acute leukaemia. *Br J Haematol* 120 (1): 1, 2003.
66. Kiehn TE, Nelson PE, Bernard EM, Edwards FF, Koziner B, Armstrong D. Catheter-associated fungemia caused by *Fusarium chlamydosporum* in a patient with lymphocytic lymphoma. *J Clin Microbiol* 21 (4): 501-4, 1985.
67. Kivivuori SM, Hovi L, Vettenranta K, Saarinen-Pihkala UM. Invasive fusariosis in two transplanted children. *Eur J Pediatr* 163 (11): 692-3, 2004.
68. Krcmery V, Jr., Jesenska Z, Spanik S, Gyarfás J, Nogova J, Botek R, Mardiak J, Sufliarsky J, Sisolakova J, Vanickova M, Kunova A, Studena M, Trupl J. Fungaemia due to *Fusarium* spp. in cancer patients. *J Hosp Infect* 36 (3): 223-8, 1997.
69. Kumar RR, Kumar BR, Shafiulla M, Lakshmaiah KC, Sridhar H. *Fusarium solani* infection in a patient with acute myelogenous leukemia--a case report. *Indian J Pathol Microbiol* 40 (4): 555-7, 1997.
70. Kurien M, Anandi V, Raman R, Brahmadathan KN. Maxillary sinus fusariosis in immunocompetent hosts. *J Laryngol Otol* 106 (8): 733-6, 1992.
71. Letscher-Bru V, Campos F, Waller J, Randriamahazaka R, Candolfi E, Herbrecht R. Successful outcome of treatment of a disseminated infection

- due to *Fusarium dimerum* in a leukemia patient. *J Clin Microbiol* 40 (3): 1100-2, 2002.
72. Leu HS, Lee AY, Kuo TT. Recurrence of *Fusarium solani* abscess formation in an otherwise healthy patient. *Infection* 23 (5): 303-5, 1995.
 73. Lieberman TW, Ferry AP, Bottone EJ. *Fusarium solani* endophthalmitis without primary corneal involvement. *Am J Ophthalmol* 88 (4): 764-7, 1979.
 74. Louie T, el Baba F, Shulman M, Jimenez-Lucho V. Endogenous endophthalmitis due to *Fusarium*: case report and review. *Clin Infect Dis* 18 (4): 585-8, 1994.
 75. Lupinetti FM, Giller RH, Trigg ME. Operative treatment of *Fusarium* fungal infection of the lung. *Ann Thorac Surg* 49 (6): 991-2, 1990.
 76. Lynn JR. *Fusarium* Keratitis Treated with Cycloheximide. *Am J Ophthalmol* 58: 637-41, 1964.
 77. Madhavan M, Ratnakar C, Veliath AJ, Kanungo R, Smile SR, Bhat S. Primary disseminated fusarial infection. *Postgrad Med J* 68 (796): 143-4, 1992.
 78. Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated *Fusarium verticillioides* in leukemia. *Ann Pharmacother* 39 (7-8): 1365-6, 2005.
 79. Mansoor D, Roobahany NA, Mazinany H, Samimagam A. Chronic *Fusarium* infection in an adult patient with undiagnosed chronic granulomatous disease. *Clin Infect Dis* 37 (7): e107-8, 2003.
 80. Matsuda T, Matsumoto T. Disseminated hyalohyphomycosis in a leukemic patient. *Arch Dermatol* 122 (10): 1171-5, 1986.
 81. Melcher GP, McGough DA, Fothergill AW, Norris C, Rinaldi MG. Disseminated hyalohyphomycosis caused by a novel human pathogen, *Fusarium napiforme*. *J Clin Microbiol* 31 (6): 1461-7, 1993.
 82. Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. *J Infect Dis* 158 (5): 1046-55, 1988.

83. Mikami R, Stemmermann GN. Keratomycosis caused by *Fusarium oxysporum*. *Am J Clin Pathol* 29 (3): 257-62, 1958.
84. Minor RL, Jr., Pfaller MA, Gingrich RD, Burns LJ. Disseminated *Fusarium* infections in patients following bone marrow transplantation. *Bone Marrow Transplant* 4 (6): 653-8, 1989.
85. Mohammedi I, Gachot B, Grossin M, Marche C, Wolff M, Vachon F. Overwhelming myocarditis due to *Fusarium oxysporum* following bone marrow transplantation. *Scand J Infect Dis* 27 (6): 643-4, 1995.
86. Mowbray DN, Paller AS, Nelson PE, Kaplan RL. Disseminated *Fusarium solani* infection with cutaneous nodules in a bone marrow transplant patient. *Int J Dermatol* 27 (10): 698-701, 1988.
87. Musa MO, Al Eisa A, Halim M, Sahovic E, Gyger M, Chaudhri N, Al Mohareb F, Seth P, Aslam M, Aljurf M. The spectrum of *Fusarium* infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. *Br J Haematol* 108 (3): 544-8, 2000.
88. Mutton KJ, Lucas TJ, Harkness JL. Disseminated fusarium infection. *Med J Aust* 2 (11): 624-5, 1980.
89. Myoken Y, Sugata T, Kyo T, Fujihara M. Oral *Fusarium* infection in a granulocytopenic patient with acute myelogenous leukemia: a case report. *J Oral Pathol Med* 24 (5): 237-40, 1995.
90. Nadler JP. Disseminated fusarial infection. *Rev Infect Dis* 12 (1): 162, 1990.
91. Nakamura Y, Xu X, Saito Y, Tateishi T, Takahashi T, Kawachi Y, Otsuka F. Deep cutaneous infection by *Fusarium solani* in a healthy child: successful treatment with local heat therapy. *J Am Acad Dermatol* 56 (5): 873-7, 2007.
92. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of *Fusarium* species. *Clin Microbiol Rev* 7 (4): 479-504, 1994.

93. Neumeister B, Bartmann P, Gaedicke G, Marre R. A fatal infection due to *Fusarium oxysporum* in a child with Wilms' tumour. Case report and review of the literature. *Mycoses* 35 (5-6): 115-9, 1992.
94. Nucci M, Anaissie E. *Fusarium* infections in immunocompromised patients. *Clin Microbiol Rev* 20 (4): 695-704, 2007.
95. Nucci M, Spector N, Lucena S, Bacha PC, Pulcheri W, Lamosa A, Derossi A, Caiuby MJ, Macieira J, Oliveira HP. Three cases of infection with *Fusarium* species in neutropenic patients. *Eur J Clin Microbiol Infect Dis* 11 (12): 1160-2, 1992.
96. Nuovo MA, Simmonds JE, Chacho MS, McKittrick JC. *Fusarium solani* osteomyelitis with probable nosocomial spread. *Am J Clin Pathol* 90 (6): 738-41, 1988.
97. Oji EO, Steele DM. *Fusarium solani* keratitis. *East Afr Med J* 59 (9): 632-8, 1982.
98. Okada H, Hamatani S, Kondo M, Imai T, Itoh S, Isobe K, Onishi S. Successful treatment of disseminated *Fusarium* infection in an infant with leukemia. *Int J Hematol* 72 (4): 494-8, 2000.
99. Ooi SP, Chen TT, Huang TH, Chang HS, Hsieh HY. Granuloma annulare-like skin lesion due to *Fusarium roseum*: therapy with ketoconazole. *Arch Dermatol* 123 (2): 167-8, 1987.
100. Page JC, Friedlander G, Dockery GL. Postoperative *Fusarium* osteomyelitis. *J Foot Surg* 21 (3): 174-6, 1982.
101. Patterson TS, Barton LL, Shehab ZM, Hutter JJ. Amphotericin B lipid complex treatment of a leukemic child with disseminated *Fusarium solani* infection. *Clin Pediatr (Phila)* 35 (5): 257-60, 1996.
102. Peltroche-Llacsahuanga H, Manegold E, Kroll G, Haase G. Case report. Pathohistological findings in a clinical case of disseminated infection with *Fusarium oxysporum*. *Mycoses* 43 (9-10): 367-72, 2000.
103. Pereiro M, Jr., Abalde MT, Zulaica A, Caeiro JL, Florez A, Peteiro C, Toribio J. Chronic infection due to *Fusarium oxysporum* mimicking lupus

- vulgaris: case report and review of cutaneous involvement in fusariosis. *Acta Derm Venereol* 81 (1): 51-3, 2001.
104. Raad I, Hachem R. Treatment of central venous catheter-related fungemia due to *Fusarium oxysporum*. *Clin Infect Dis* 20 (3): 709-11, 1995.
 105. Rabodonirina M, Piens MA, Monier MF, Gueho E, Fiere D, Mojon M. *Fusarium* infections in immunocompromised patients: case reports and literature review. *Eur J Clin Microbiol Infect Dis* 13 (2): 152-61, 1994.
 106. Repiso T, Garcia-Patos V, Martin N, Creus M, Bastida P, Castells A. Disseminated fusariosis. *Pediatr Dermatol* 13 (2): 118-21, 1996.
 107. Rezai KA, Elliott D, Plous O, Vazquez JA, Abrams GW. Disseminated *Fusarium* infection presenting as bilateral endogenous endophthalmitis in a patient with acute myeloid leukemia. *Arch Ophthalmol* 123 (5): 702-3, 2005.
 108. Richardson SE, Bannatyne RM, Summerbell RC, Milliken J, Gold R, Weitzman SS. Disseminated fusarial infection in the immunocompromised host. *Rev Infect Dis* 10 (6): 1171-81, 1988.
 109. Rippon JW, Larson RA, Rosenthal DM, Clayman J. Disseminated cutaneous and peritoneal hyalohyphomycosis caused by *Fusarium* species: three cases and review of the literature. *Mycopathologia* 101 (2): 105-11, 1988.
 110. Ritchie EB, Pinkerton ME. *Fusarium oxysporum* infection of the nail; report of cases. *AMA Arch Derm* 79 (6): 705-8, 1959.
 111. Robertson MJ, Socinski MA, Soiffer RJ, Finberg RW, Wilson C, Anderson KC, Bosserman L, Sang DN, Salkin IF, Ritz J. Successful treatment of disseminated *Fusarium* infection after autologous bone marrow transplantation for acute myeloid leukemia. *Bone Marrow Transplant* 8 (2): 143-5, 1991.
 112. Roden M. Epidemiology and outcome of Zygomycosis: A review of 929 reportet cases. *CID* 41, 2005.

113. Rodriguez CA, Lujan-Zilbermann J, Woodard P, Andreansky M, Adderson EE. Successful treatment of disseminated fusariosis. *Bone Marrow Transplant* 31 (5): 411-2, 2003.
114. Romano C, Miracco C, Difonzo EM. Skin and nail infections due to *Fusarium oxysporum* in Tuscany, Italy. *Mycoses* 41 (9-10): 433-7, 1998.
115. Rombaux P, Eloy P, Bertrand B, Delos M, Doyen C. Lethal disseminated *Fusarium* infection with sinus involvement in the immunocompromised host: case report and review of the literature. *Rhinology* 34 (4): 237-41, 1996.
116. Rothe A, Seibold M, Hoppe T, Seifert H, Engert A, Caspar C, Karthaus M, Fatkenheuer G, Bethe U, Tintelnot K, Cornely OA. Combination therapy of disseminated *Fusarium oxysporum* infection with terbinafine and amphotericin B. *Ann Hematol* 83 (6): 394-7, 2004.
117. Rowsey JJ, Acers TE, Smith DL, Mohr JA, Newsom DL, Rodriguez J. *Fusarium oxysporum* endophthalmitis. *Arch Ophthalmol* 97 (1): 103-5, 1979.
118. Ruiz N, Fernandez-Martos C, Romero I, Pla A, Maiquez J, Calatrava A, Guillem V. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. *J Clin Oncol* 25 (22): 3376-7, 2007.
119. Sagnelli C, Fumagalli L, Prigitano A, Baccari P, Magnani P, Lazzarin A. Successful voriconazole therapy of disseminated *Fusarium verticillioides* infection in an immunocompromised patient receiving chemotherapy. *J Antimicrob Chemother* 57 (4): 796-8, 2006.
120. Sampathkumar P, Paya CV. *Fusarium* infection after solid-organ transplantation. *Clin Infect Dis* 32 (8): 1237-40, 2001.
121. Sander A, Beyer U, Amberg R. Systemic *Fusarium oxysporum* infection in an immunocompetent patient with an adult respiratory distress syndrome (ARDS) and extracorporeal membrane oxygenation (ECMO). *Mycoses* 41 (3-4): 109-11, 1998.

122. Savir H, Henig E, Lehrer N. Exogenous mycotic infections of the eye and adnexia. *Ann Ophthalmol* 10 (8): 1013-8, 1978.
123. Sayama K, Ohtsuka H, Shiraishi S, Miki Y, Tada M, Matsumoto T. Squamous cell carcinoma arising in long-standing granulomatous hyalohyphomycosis caused by *Fusarium solani*. *Arch Dermatol* 127 (11): 1735-7, 1991.
124. Schneller FR, Gulati SC, Cunningham IB, O'Reilly RJ, Schmitt HJ, Clarkson BD. *Fusarium* infections in patients with hematologic malignancies. *Leuk Res* 14 (11-12): 961-6, 1990.
125. Segal BH, Walsh TJ, Liu JM, Wilson JD, Kwon-Chung KJ. Invasive infection with *Fusarium chlamydosporum* in a patient with aplastic anemia. *J Clin Microbiol* 36 (6): 1772-6, 1998.
126. Singh H, Jamal F, Marahakim MN, Song CC. *Fusarium solani* keratitis. First report from Malaysia. *Med J Malaysia* 36 (2): 89-91, 1981.
127. Spielberger RT, Falleroni MJ, Coene AJ, Larson RA. Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with *Fusarium* in a granulocytopenic patient. *Clin Infect Dis* 16 (4): 528-30, 1993.
128. Sturm AW, Grave W, Kwee WS. Disseminated *Fusarium oxysporum* infection in patient with heatstroke. *Lancet* 1 (8644): 968, 1989.
129. Summerbell RC, Richardson SE, Kane J. *Fusarium proliferatum* as an agent of disseminated infection in an immunosuppressed patient. *J Clin Microbiol* 26 (1): 82-7, 1988.
130. Tu EY, McCartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). *Am J Ophthalmol* 143 (2): 222-227, 2007.
131. Valenstein P, Schell WA. Primary intranasal *Fusarium* infection. Potential for confusion with rhinocerebral zygomycosis. *Arch Pathol Lab Med* 110 (8): 751-4, 1986.

132. Valentine NB, Wahl JH, Kingsley MT, Wahl KL. Direct surface analysis of fungal species by matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun Mass Spectrom* 16 (14): 1352-7, 2002.
133. van Dijk E, van den Berg WH, Landwehr AJ. *Fusarium solani* infection of a hypertensive leg ulcer in a diabetic. *Mykosen* 23 (11): 603-6, 1980.
134. Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. *Eur J Clin Microbiol Infect Dis* 14 (8): 697-9, 1995.
135. Vincent AL, Cabrero JE, Greene JN, Sandin RL. Successful voriconazole therapy of disseminated *Fusarium solani* in the brain of a neutropenic cancer patient. *Cancer Control* 10 (5): 414-9, 2003.
136. Viscoli C, Castagnola E, Moroni C, Garaventa A, Manno G, Savioli C. Infection with *Fusarium* species in two children with neuroblastoma. *Eur J Clin Microbiol Infect Dis* 9 (10): 773-6, 1990.
137. Viviani MA, Cofrancesco E, Boschetti C, Tortorano AM, Cortellaro M. Eradication of *Fusarium* infection in a leukopenic patient treated with liposomal amphotericin B. *Mycoses* 34 (5-6): 255-6, 1991.
138. Wheeler MS, McGinnis MR, Schell WA, Walker DH. *Fusarium* infection in burned patients. *Am J Clin Pathol* 75 (3): 304-11, 1981.
139. Wickern GM. *Fusarium* allergic fungal sinusitis. *J Allergy Clin Immunol* 92 (4): 624-5, 1993.
140. Willemsen MJ, De Coninck AL, Coremans-Pelseneer JE, Marichal-Pipeleers MA, Roseeuw DI. Parasitic invasion of *Fusarium oxysporum* in an arterial ulcer in an otherwise healthy patient. *Mykosen* 29 (6): 248-52, 1986.
141. Wolff MA, Ramphal R. Use of amphotericin B lipid complex for treatment of disseminated cutaneous fusarium infection in a neutropenic patient. *Clin Infect Dis* 20 (6): 1568-9, 1995.
142. Young NA, Kwon-Chung KJ, Kubota TT, Jennings AE, Fisher RI. Disseminated infection by *Fusarium moniliforme* during treatment for malignant lymphoma. *J Clin Microbiol* 7 (6): 589-94, 1978.

143. Zapater RC, Arrechea A. Mycotic keratitis by *Fusarium*. A review and report of two cases. *Ophthalmologica* 170 (1): 1-12, 1975.

7. Curriculum vitae

Doris Schmidig aus Schaffhausen

- 19.11.1980 geboren in Schaffhausen
- 1987-1995 Primar-, und Sekundarschule Schaffhausen
- 1995-2000 Kantonsschule Schaffhausen, Maturität Typ B
- 2000-2006 Medizinstudium in Fribourg und Zürich
- 11/2006 Staatsexamen an der Universität Zürich
- 2007-2008 Assistenzärztin Chirurgie, Kantonsspital Schaffhausen
- 2009-2010 Assistenzärztin Innere Medizin, Stadtspital Waid
- 2011 Assistenzärztin Innere Medizin, Universitätsspital Zürich